CN111617089B - Novel triton-silver composite antibacterial reagent and application thereof - Google Patents
Novel triton-silver composite antibacterial reagent and application thereof Download PDFInfo
- Publication number
- CN111617089B CN111617089B CN202010475779.8A CN202010475779A CN111617089B CN 111617089 B CN111617089 B CN 111617089B CN 202010475779 A CN202010475779 A CN 202010475779A CN 111617089 B CN111617089 B CN 111617089B
- Authority
- CN
- China
- Prior art keywords
- silver
- triton
- antibacterial
- novel
- gel
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/38—Silver; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/075—Ethers or acetals
- A61K31/085—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
- A61K31/09—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon having two or more such linkages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/74—Synthetic polymeric materials
- A61K31/765—Polymers containing oxygen
- A61K31/77—Polymers containing oxygen of oxiranes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Inorganic Chemistry (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Communicable Diseases (AREA)
Abstract
The invention provides a novel triton-silver composite antibacterial reagent and application thereof, wherein the novel triton-silver composite antibacterial reagent is a novel antibacterial drug reagent which is prepared by taking triton and silver as raw materials and adding a pharmaceutically acceptable carrier, and has excellent composite antibacterial performance, the silver is silver ions or nano silver, the concentration of the triton is lower than 1%, and the concentration of the silver ions or the nano silver is lower than 100 mug/mL. The triton and the silver have a synergistic antibacterial effect. The novel triton-silver composite antibacterial reagent provided by the invention can effectively reduce the usage amount of silver ions or nano silver, thereby obviously reducing the accompanying high cytotoxicity and potential discoloration defects, obviously improving the antibacterial effect of the silver ions or the nano silver, and having important research and clinical significance.
Description
Technical Field
The invention belongs to the field of antibacterial agent reagents, and particularly relates to a novel triton-silver composite antibacterial reagent and application thereof.
Background
Antibacterial drugs are one of the most widely used drugs in clinical practice at present. The combination of different antibacterial agents has long been used. The reasonable combined medication has the advantages that the single medication is incomparable, thereby reducing adverse reaction, reducing drug-induced diseases, reducing drug resistance and improving curative effect.
Antimicrobial metal ions, e.g. silver ions (Ag)+) Has broad-spectrum antibacterial activity and no obvious bacterial drug resistance. However, the high cytotoxicity and potential discoloration of silver ion severely limits its wide application in clinical medicine. Detergents are widely used as solubilizers for biological membranes and can be classified into ionic surfactants (e.g., chlorhexidine, chlorexidine, CHX) and nonionic surfactants (e.g., Triton X-100, TX-100). Due to the amphiphilic characteristic of the detergent, the detergent can enter cell membranes at low concentration and dissolve the membranes at high concentration. CHX is widely applied to clinical treatment due to its high-efficiency inhibition effect on a series of gram-positive and gram-negative bacteria, but its application is always restricted by its high toxicity. TX-100 is a soluble amphiphilic molecule as a non-ionic detergent that is capable of binding to liposomes and cell membranes and increasing membrane penetration by rearranging the anisotropic nature of lipid rafts. TX-100 is a necessary tool for studying biofilms, but is rarely used as an antibacterial drug due to its limited bacteriostatic activity.
In order to overcome the above disadvantages, researchers have tried to combine silver ions or nano silver with other metal ions, detergents, etc. to enhance antibacterial effect and reduce side effects. When CHX is used in combination with silver ions or nano-silver, the antibacterial effect is enhanced, but a novel enhanced antibacterial drug reagent is developed by the cooperation of the silver ions or nano-silver and TX-100, and no report is found yet.
Disclosure of Invention
The invention aims to provide a novel triton-silver composite antibacterial reagent, which is a novel antibacterial medicament reagent with composite excellent antibacterial performance and is prepared by taking triton (TritonX-100, TX-100) and silver as main raw materials, wherein the triton and the silver have a synergistic antibacterial effect.
The second purpose of the invention is to provide the application of the novel triton-silver composite antibacterial reagent in antibacterial drugs, the novel triton-silver composite antibacterial reagent can obviously reduce the usage amount of silver ions or nano silver, reduce the accompanying high cytotoxicity and potential discoloration problems, simultaneously enhance the antibacterial effect, and has important research and clinical significance.
One of the purposes of the invention adopts the following technical scheme:
the novel triton-silver composite antibacterial reagent is a novel antibacterial medicinal reagent with composite excellent antibacterial performance, which is prepared by taking triton and silver as raw materials and adding a pharmaceutically acceptable carrier, wherein the silver is silver ions or nano silver, the concentration of the triton is lower than 1%, and the concentration of the silver ions or the nano silver is lower than 100 mu g/mL.
The triton and the silver have a synergistic antibacterial effect.
The silver ions are derived from silver nitrate or silver sulfadiazine or other silver ion compounds.
The carrier is a liquid, gel or solid.
The gel comprises collagen gel and methyl cellulose gel, and the solid comprises chitosan scaffold, high molecular polymer scaffold and fiber fabric.
The novel triton-silver composite antibacterial agent is granules, tablets, pills, patches, capsules, injections, sprays or dispersants and the like.
The second purpose of the invention is realized by adopting the following technical scheme:
an application of a novel triton-silver composite antibacterial agent in antibacterial drugs.
The fungus includes enterococcus faecalis.
The novel triton-silver composite antibacterial agent is used as an antibacterial drug for mucosal administration, skin external application, in vivo implantation and dental administration, and the mucosal administration adopts a solution, a spray and an aerosol; the skin external administration adopts patch, liniment, lotion, gel, liniment, and ointment; the dental administration adopts solution, gel, paste and the like; the in vivo implant adopts a stent, a filling material, a slow release body and the like.
Compared with the prior art, the invention has the beneficial effects that:
(1) the novel triton-silver composite antibacterial reagent provided by the invention comprises two effective components of triton and silver, and the novel triton-silver composite antibacterial reagent can effectively reduce the usage amount of silver ions or nano silver, so that the accompanying high cytotoxicity and potential discoloration defects of the novel triton-silver composite antibacterial reagent are obviously reduced.
(2) The novel triton-silver composite antibacterial reagent provided by the invention can obviously improve the antibacterial effect of silver ions or nano silver, has a synergistic antibacterial effect, and has important research and clinical significance.
(3) The novel triton-silver composite antibacterial reagent provided by the invention can be applied to various infection control fields in various application forms.
Drawings
FIG. 1 shows Ag in an example of the present invention++ TX-100 Effect on enterococcus faecalis colony formation 24 hours;
in the figure, A-I each represent 25. mu.g/mLAgNO3+0.02％TX-100，50μg/mLAgNO3+0.02％TX-100,75μg/mLAgNO3+0.02％TX-100，100μg/mLAgNO3+0.02％TX-100，25μg/mLAgNO3+0.04％TX-100，50μg/mLAgNO3+0.04％TX-100，75μg/mLAgNO3+0.04％TX-100，100μg/mLAgNO3+ 0.04% TX-100, 2% CHX group of bacterial colonies forming the pattern;
FIG. 2 shows Ag in an embodiment of the present invention+Bacterial colony score for 24 hour effect on enterococcus faecalis colony formation by + TX-100 synergy (.: significant difference compared to positive control, P)<0.05)；
FIG. 3 shows Ag in an embodiment of the present invention+Dynamic antibacterial score for the effect of + TX-100 synergy on enterococcus faecalis (: significant difference compared to positive control group, P)<0.05)；
FIG. 4 shows Ag in an embodiment of the present invention++ TX-100 synergy cytotoxicity on MC3T3 cells (significant difference compared to negative control, P)<0.05)。
Detailed Description
The novel triton-silver complex antibacterial agent and the application thereof of the present invention will be further described with reference to the following specific examples, but it should not be construed that the scope of the present invention is limited to the following examples, and all the technologies realized based on the above contents of the present invention are within the scope of the present invention.
Taking a mixed solution of silver ions and TX-100 as an example, the performance of the novel antibacterial drug is determined aiming at gram-positive facultative anaerobes such as enterococcus faecalis which have strong resistance to extremely severe environments such as nutrition deficiency and high alkaline pH values.
EXAMPLES measurement of synergistic antibacterial Properties of silver ion and TX-100 Mixed solution
1.1 Minimum Inhibitory Concentration (MIC) and bactericidal concentration (MBC) assay
Preparation of silver nitrate (AgNO) containing 0, 0.02%, 0.04%, 0.08%, 0.1%, 0.2%, 1% or 2% TX-100 with sterilized double distilled water3) Solution (AgNO)3The concentration is as follows: 600, 400, 300, 200, 100, 50, 25, 0. mu.g/mL), 50. mu.L of the above mixed solution was added to a 96-well plate. An enterococcus faecalis (ATCC) suspension having an absorbance value of 1 at 600nm was subjected to gradient dilution to 2X 10 in BHI medium of double concentration5CFUs/mL, 50. mu.L of diluted bacterial solution was added to the above 96-well plate and incubated anaerobically at 37 ℃ for 24 hours in the dark. The absorbance at 600nm, which is closest to that of the blank medium, was read with a microplate reader (Power Wave XS2, BioTek Instruments, VT, USA), and AgNO3The group with the lowest solution concentration is AgNO under the action of the concentration TX-1003The MIC of (1). From AgNO3Taking 10 μ L of mixed solution from the group with the solution concentration higher than MIC, coating on BHI agar plate, calculating colony forming unit number, and when the concentration is less than 4% of that of blank control group (BHI culture medium + enterococcus faecalis), the concentration is equal to the concentration of AgNO under the action of TX-1003The MBC of (1). The operation is carried out under the condition of keeping out light and asepsis. Repeat six times. The results are shown in table 1:
TABLE 1 AgNO at different concentrations of TX-1003MIC and MBC of
The results show that a small amount of TX-100 (0.01%, 0.02%) makes AgNO available3The MIC and the MBC of the compound are obviously reduced, AgNO3The bacteriostatic effect is greatly improved; and AgNO as the concentration of TX-100 increases3The MIC and MBC of (A) gradually decrease, and the addition ofAgNO can be achieved when the TX-100 is 0.04 percent3MIC and MBC were lowest, and their concentrations were reduced by 12-fold. And when the concentration of TX-100 is continuously increased, the MIC value and the MBC value of the silver ion are kept unchanged, which indicates that the concentration of the silver ion reaches the lowest concentration which can fully exert the synergistic antibacterial effect with TX-100.
1.2 colony Forming Unit count experiment
Taking enterococcus faecalis suspension (1X 10) with absorbance value of 1 at 600nm9CFUs/mL), 900. mu.L of enterococcus faecalis suspension was mixed with 100. mu.L of AgNO-containing suspension3Mixing with TX-100 solution to make AgNO3The final concentration of (b) was 25. mu.g/mL, 50. mu.g/mL, 75. mu.g/mL, 100. mu.g/mL, and the final concentration of TX-100 was 0.02% or 0.04%. After mixing well, incubation was carried out at 4 ℃ for 24 hours in the dark. After 24 hours, 5. mu.L of each was uniformly spread on BHI agar plates, and anaerobically cultured at 37 ℃ for 24 hours in the absence of light. The negative control group is that the bacterial liquid and 100 mu L of sterilized double distilled water are incubated together, and the positive control group is that the bacterial liquid and 100 mu L of 20% CHX are incubated together, namely the final concentration is 2% CHX. The operations are carried out under the conditions of light protection and asepsis. Repeat 6 times. A4-score scoring system is adopted, and a specific scoring mechanism is as follows:
score 1: the number of bacteria on BHI agar plates was 0.
And (3) scoring 2: there were less than 100 bacteria on BHI agar plates.
And 3, scoring: there were fewer than 500 bacteria on BHI agar plates.
Score 4: there were more than 500 bacteria on BHI agar plates.
As shown in FIGS. 1 and 2, after 24 hours, all experimental groups exhibited significant antibacterial effects compared to the negative control group, in which the amount of bacteria was not counted at all, and with AgNO3And the increase of the concentration of TX-100, the antibacterial effect is more obvious, 75 and 100 mu g/mLAgNO3+ 0.02% of TX-100 group, and 75, 100. mu.g/mLAgNO3The + 0.04% TX-100 group can play a stable complete bactericidal effect, and has no obvious difference with the 2% CHX group. (significant differences compared to the positive control group, P)<0.05)
1.3 dynamic antibacterial experiments
Taking enterococcus faecalis suspension with absorbance value of 1 at 600nm, and concentrating at double concentrationDilution to 2X 10 in BHI Medium8CFUs/mL. 500 mu LAgNO3Adding 500 μ L diluted enterococcus faecalis suspension into mixed solution of TX-100 to make AgNO3The final concentration of the mixture and TX-100 was the same as that in 1.2, and the mixture was incubated in a 37 ℃ incubator in the dark. At 1, 3, 6 and 9 hours, 5. mu.L of each was evenly spread on BHI agar plates and anaerobically cultured at 37 ℃ for 24 hours in the dark. The negative control group was incubated with 500. mu.L of the bacterial liquid and 500. mu.L of sterile double distilled water, and the positive control group was incubated with 500. mu.L of the bacterial liquid and 500. mu.L of 4% CHX. The operations are carried out under the conditions of light protection and asepsis. Repeat 6 times. The scoring system was identical to that in 1.2. The results are shown in table 2 and fig. 3:
TABLE 2 AgNO3Dynamic antibacterial Effect of + TX-100
The results in FIG. 3 show that the dynamic antimicrobial scoring results further confirm AgNO3+ TX-100 significant synergistic antibacterial action. In addition to being dose-dependent, there is a time-dependent relationship between them. Dynamic antibacterial scoring result shows AgNO with different concentrations3The score of the + TX-100 group showed a gradual decrease with time, indicating that the antibacterial effect was also gradually increased with the increase of the action time. After 3 hours, 100. mu.g/mLAgNO3+ 0.02% of TX-100 group, 75. mu.g/mLAgNO3+ 0.04% TX-100 group and 100. mu.g/mLAgNO3+ 0.04% of TX-100 groups showed no bacterial growth, and the groups with no bacterial growth increased gradually with time, whereas after 9 hours, only 25. mu.g/mLAgNO3+ 0.02% of TX-100 group and 25. mu.g/mLAgNO3The + 0.04% TX-100 group still had bacterial survival. In addition, the standard deviation of all groups with a score of 1 was 0, indicating AgNO3The + TX-100 can play an extremely stable complete bactericidal action.
1.4 cytotoxic assay
The mixture was tested for cytotoxicity using the CCK-8 kit. Preparation of AgNO using alpha-MEM Medium containing 1% penicillin/streptomycin double antibody and 10% fetal bovine serum3(25,50,75, 100. mu.g/mL), TX-100 (0.02%, 0.04%) and Ag++ TX-100 and filter sterilized using a sterile 0.22 μm diameter filter. Add 100. mu.L of 10X 10 concentration to 96-well plates3MC3T3 cells (ATCC) suspension at individual/mL, and cultured at 37 ℃ for 24 hours to allow the cells to adhere. After 24 hours, the medium in the 96-well plate was aspirated, and 200. mu.L of fresh α -MEM medium and 10. mu.L of the above-mentioned mixture were added thereto, followed by co-culture at 37 ℃ in the dark. A negative control group (to which only 210. mu.L of alpha-MEM medium was added at the time of changing the medium) and a positive control group (to which 200. mu.L of alpha-MEM medium and 10. mu.L of 2% CHX were added at the time of changing the medium) were provided at the same time. After 24 hours of incubation, the liquid in each well of the 96-well plate was aspirated, and the plate was rinsed 3 times with 200. mu.L LPBS, and finally 100. mu.L of α -MEM culture medium and 10. mu.L of LCCK-8 reagent were added, incubated together at 37 ℃ in the dark for 1 hour, and then the absorbance of the 96-well plate at a wavelength of 450nm was measured using a microplate reader. The above groups were repeated 6 times.
The results are shown in FIG. 4, and the CCK-8 test shows that AgNO at different concentrations is compared with the negative control group3The + TX-100 group has no obvious inhibition effect on cell growth (P)>0.05), while the positive control group, i.e. the 2% CHX group, had a significant inhibitory effect on cell growth. (P)<0.05)
In conclusion, compared with silver ions or nano silver, the mixed solution of silver ions and TX-100 can inhibit the growth of pathogenic bacteria under the action of a lower-dose medicament, enhance the antibacterial effect, reduce the side effect brought by the medicament and have a synergistic antibacterial effect; compared with the traditional antibacterial agent chlorhexidine, the antibacterial agent has the advantages that the cytotoxicity of the antibacterial agent is reduced while the antibacterial effect similar to that of the chlorhexidine is kept, so that a pharmaceutically acceptable carrier is added into silver and TX-100, a novel triton-silver composite antibacterial agent can be prepared, the novel antibacterial agent has composite excellent antibacterial performance, and the novel antibacterial agent can be used as a novel antibacterial agent to be applied to prevention and treatment of bacterial infectious diseases.
Claims (5)
1. The application of the triton-silver composite antibacterial agent in the preparation of antibacterial drugs is characterized in that: the triton-silver composite antibacterial agent is an antibacterial drug agent with composite excellent antibacterial performance, which is prepared by taking triton and silver nitrate as raw materials and adding a pharmaceutically acceptable carrier, wherein the concentration of the triton is 0.02-0.04%, and the concentration of the silver nitrate is 75-100 mug/mL; the triton and the silver nitrate have a synergistic antibacterial effect; the fungus is enterococcus faecalis.
2. The use of claim 1, wherein: the carrier is a liquid, gel or solid.
3. Use according to claim 2, characterized in that: the gel comprises collagen gel and methyl cellulose gel, and the solid comprises chitosan scaffold and high molecular polymer scaffold.
4. The use of claim 1, wherein: the triton-silver composite antibacterial agent is granules, tablets, pills, patches, capsules, injections, sprays or dispersing agents.
5. The use of claim 1, wherein: the triton-silver composite antibacterial agent is used as an antibacterial drug for mucosal administration, skin external application, in vivo implant and dental administration, and the mucosal administration adopts solution, spray and aerosol; the skin external administration adopts patch, liniment, lotion, gel, liniment, and ointment; the dental administration adopts solution, gel and paste; the in vivo implant adopts a stent, a filling material and a slow release body.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010475779.8A CN111617089B (en) | 2020-05-29 | 2020-05-29 | Novel triton-silver composite antibacterial reagent and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010475779.8A CN111617089B (en) | 2020-05-29 | 2020-05-29 | Novel triton-silver composite antibacterial reagent and application thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN111617089A CN111617089A (en) | 2020-09-04 |
| CN111617089B true CN111617089B (en) | 2021-07-20 |
Family
ID=72267373
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202010475779.8A Active CN111617089B (en) | 2020-05-29 | 2020-05-29 | Novel triton-silver composite antibacterial reagent and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN111617089B (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112675199B (en) * | 2021-01-08 | 2022-02-01 | 武汉大学 | Drug combination and application thereof |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1539898A (en) * | 2003-11-03 | 2004-10-27 | 吉林省纳米技术应用工程（集团）股份 | Method of producing Nano Functional agent for protecting stone surface and water proof, soil repellent and antibacterial dimension stone |
| CN106582326A (en) * | 2015-10-20 | 2017-04-26 | 中国石油化工股份有限公司 | Antibacterial composite nano-filtration membrane and preparation method and application thereof |
| CN107333798A (en) * | 2017-06-28 | 2017-11-10 | 华东理工大学 | A kind of preparation method of nano silver-group compound disinfectant |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8527687D0 (en) * | 1985-11-09 | 1985-12-11 | Wales University Of College Of | Silver intensification of diaminobenzidine |
| US5186984A (en) * | 1990-06-28 | 1993-02-16 | Monsanto Company | Silver coatings |
| US6759040B1 (en) * | 1997-09-12 | 2004-07-06 | University Of Maryland, College Park | Preparation and use of biofilm-degrading, multiple-specificity, hydrolytic enzyme mixtures |
-
2020
- 2020-05-29 CN CN202010475779.8A patent/CN111617089B/en active Active
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1539898A (en) * | 2003-11-03 | 2004-10-27 | 吉林省纳米技术应用工程（集团）股份 | Method of producing Nano Functional agent for protecting stone surface and water proof, soil repellent and antibacterial dimension stone |
| CN106582326A (en) * | 2015-10-20 | 2017-04-26 | 中国石油化工股份有限公司 | Antibacterial composite nano-filtration membrane and preparation method and application thereof |
| CN107333798A (en) * | 2017-06-28 | 2017-11-10 | 华东理工大学 | A kind of preparation method of nano silver-group compound disinfectant |
Non-Patent Citations (4)
| Title |
|---|
| Label-free NIR-SERS discrimination and detection of foodborne bacteria by in situ synthesis of Ag colloids;Longyan Chen et al;《Chen et al. J Nanobiotechnol》;20150625;第13卷(第45期);第1-9页 * |
| 化探样品中金、银、铜的野外现场快速联合测定黄原醋棉富集分离金试剂液珠萃取比色法;薛光;《分析试验室》;19931231;第12卷(第5期);第41-43页 * |
| 纳米银的制备及稳定性研究;高小宁;《中国优秀硕士学位论文全文数据库 工程科技I辑》;B014-45;20190115;正文第3页第1.1.5部分抗菌性；摘要部分及正文第42-44页 * |
| 高小宁.纳米银的制备及稳定性研究.《中国优秀硕士学位论文全文数据库 工程科技I辑》.B014-45,2019,正文第3页第1.1.5部分抗菌性；摘要部分及正文第42-44页. * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN111617089A (en) | 2020-09-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR101955636B1 (en) | A composition comprising an antibiotic and a dispersant or anti-adhesive agent | |
| Devhare et al. | Acid neutralizing capacity and antimicrobial potential of selected solvent extract from various indigenous plants | |
| CN111617089B (en) | Novel triton-silver composite antibacterial reagent and application thereof | |
| US11793849B2 (en) | Method of Chinese herbal medicine extract used for treating multiple diseases caused by drug resistant bacteria infection | |
| Tangsuksan et al. | Antimicrobial and anti-inflammatory effects of α-mangostin soluble film | |
| CN112675199B (en) | Drug combination and application thereof | |
| CN111419829B (en) | Application of honokiol in inhibiting streptococcus suis or biofilm thereof | |
| Kzar | Antimicrobial and biofilm inhibitory activity of nanoparticles against clinical isolates from urinary tract infection | |
| Kim et al. | Biocompatibility evaluation of feldspathic porcelain with nano-sized silver ion particles | |
| CN114456239B (en) | Lithospermum and external antibacterial peptide gel preparation prepared from same and application | |
| WO2005107774A1 (en) | Pharmaceutical wound healing composition | |
| INOUYE et al. | Biological properties of streptonigrin derivatives I. antimicrobial and cytocidal activities | |
| CN114617863B (en) | Antibacterial composition and application thereof | |
| WO2012123924A2 (en) | Antimicrobial composition | |
| CN111686243A (en) | Composition for inhibiting oral pathogenic bacteria and application thereof | |
| CN114767708B (en) | Stable gynecological antibacterial composition and gynecological care solution | |
| CN112316156B (en) | Collagen repair membrane with oxidation resistance and antibacterial property, preparation method and application thereof | |
| CN112194588B (en) | Application of naphthalene ring compound in preparation of products for preventing and treating oral bacteria | |
| CN117442622A (en) | Use of duckbill alkaloid hydrochloride in preparation of medicine for inhibiting formation of bacterial biofilm | |
| US20230059230A1 (en) | Chronic wound healing composition and application thereof | |
| CN104892694A (en) | Sucrose sulfate copper type compound as well as preparation method and application thereof | |
| CN117777250A (en) | Antibacterial peptide PA9 for inhibiting periodontal pathogenic bacteria of oral cavity and application thereof | |
| Perego | Dextran-shelled oxygen-loaded nanodroplets promote Enterococcus faecalis killing and reduce macrophages-mediated inflammation | |
| Choi et al. | Surface Characterization and Antimicrobial Efficacy of Denture Base Resin Coated with Glycyrrhiza uralensis extract. | |
| CN117379434A (en) | Ceftazidime composition for effectively inhibiting pseudomonas aeruginosa biofilm bacteria |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |